Baseline glycolytic tumor burden predicts response and survival in NSCLC and melanoma patients treated with immune checkpoint inhibitors (2021)
- Authors:
- USP affiliated authors: CUNHA, FERNANDO DE QUEIROZ - FMRP ; CORDEIRO, SAULO DA SILVA - FMRP ; WANDERLEY, CARLOS WAGNER DE SOUZA - FMRP ; MARIN, JOSÉ FLÁVIO GOMES - FM
- Unidades: FMRP; FM
- DOI: 10.1136/jitc-2021-SITC2021.055
- Subjects: EXONS; LINFÓCITOS; MELANOMA; IMUNOLOGIA
- Language: Inglês
- Imprenta:
- Source:
- Título: Journal for ImmunoTherapy of Cancer
- ISSN: 2051-1426
- Volume/Número/Paginação/Ano: v. 9, n. 11, suppl. 2, p. A62-A63, 2021
- Conference titles: Annual Meeting of Society for Immunotherapy of Cancer's
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
CORDEIRO, Saulo da Silva et al. Baseline glycolytic tumor burden predicts response and survival in NSCLC and melanoma patients treated with immune checkpoint inhibitors. Journal for ImmunoTherapy of Cancer. London: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1136/jitc-2021-SITC2021.055. Acesso em: 12 fev. 2026. , 2021 -
APA
Cordeiro, S. da S., Wanderley, C. W. de S., Marin, J. F. G., Macedo, M. de, Nascimento, E., Antonacio, F. F., et al. (2021). Baseline glycolytic tumor burden predicts response and survival in NSCLC and melanoma patients treated with immune checkpoint inhibitors. Journal for ImmunoTherapy of Cancer. London: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1136/jitc-2021-SITC2021.055 -
NLM
Cordeiro S da S, Wanderley CW de S, Marin JFG, Macedo M de, Nascimento E, Antonacio FF, Cunha F de Q, Castro Junior G de C. Baseline glycolytic tumor burden predicts response and survival in NSCLC and melanoma patients treated with immune checkpoint inhibitors [Internet]. Journal for ImmunoTherapy of Cancer. 2021 ; 9( 11): A62-A63.[citado 2026 fev. 12 ] Available from: https://doi.org/10.1136/jitc-2021-SITC2021.055 -
Vancouver
Cordeiro S da S, Wanderley CW de S, Marin JFG, Macedo M de, Nascimento E, Antonacio FF, Cunha F de Q, Castro Junior G de C. Baseline glycolytic tumor burden predicts response and survival in NSCLC and melanoma patients treated with immune checkpoint inhibitors [Internet]. Journal for ImmunoTherapy of Cancer. 2021 ; 9( 11): A62-A63.[citado 2026 fev. 12 ] Available from: https://doi.org/10.1136/jitc-2021-SITC2021.055 - Tumor glycolytic profiling through 18F-FDG PET/CT predicts immune checkpoint inhibitor efficacy in advanced NSCLC
- Targeting PARP1 to enhance anticancer checkpoint immunotherapy response: rationale and clinical implications
- Glycolytic tumor burden on pretreatment 18F-FDG PET/CT correlates with response and survival in metastatic NSCLC undergoing immune checkpoint inhibitors
- Neuraminidase inhibitors rewire neutrophil function in vivo in murine sepsis and ex vivo in COVID-19
- Neuraminidase is a host‐directed approach to regulate neutrophil responses in sepsis and COVID‐19
- Estudo de pontos de checagem e análise de riscos para PACS implementados em serviços de computação de nuvem
- Desenvolvimento e aplicação de método semiquantitativo do esqueleto total em exames de 18F-NaF PET/CT: estabelecimento de valores normais em pacientes não metastáticos e avaliação prognóstica em pacientes com metástases ósseas
- Nanobodies dismantle post-pyroptotic ASC specks and counteract inflammation in vivo
- Platelets fuel the inflammasome activation of innate immune cells
- Paradoxical interaction between cancer and long-term postsepsis disorder: impairment of de novo carcinogenesis versus favoring the growth of established tumors
Informações sobre o DOI: 10.1136/jitc-2021-SITC2021.055 (Fonte: oaDOI API)
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
003207574.pdf |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
